<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: Prospective Grant of Start-up Exclusive Evaluation Option Patent License: “The Development and Use of Diazeniumdiolated and Hybrid Diazeniumdiolated Compounds for the Treatment of Ovarian Cancer in Humans”</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: Prospective Grant of Start-up Exclusive Evaluation Option Patent License: “The Development and Use of Diazeniumdiolated and Hybrid Diazeniumdiolated Compounds for the Treatment of Ovarian Cancer in Humans”</h1>
    <p class="timestamp">Published: 2017-04-04 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of a Start-up Exclusive Evaluation Option License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to Tar Meta Biosciences, Inc. ("TarMeta") located in King of Prussia, PA, USA.</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Notice</p>
    <p><strong>Agency:</strong> Health and Human Services Department, National Institutes of Health</p>
    <p><strong>Document Number:</strong> 2017-06545</p>
    <p><strong>Publication Date:</strong> 2017-04-04</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2017/04/04/2017-06545/prospective-grant-of-start-up-exclusive-evaluation-option-patent-license-the-development-and-use-of">https://www.federalregister.gov/documents/2017/04/04/2017-06545/prospective-grant-of-start-up-exclusive-evaluation-option-patent-license-the-development-and-use-of</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2017-06545</div>
    <p><a href="index.html">Back to Breaking News Wire</a></p>
</body>
</html>
